Towards the development of specific antidotes: Idarucizumab for reversal of dabigatran effects.
Eva-Luise
EL
Hobl
Bernd Jilma, MD, Department of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria, Tel.: +43 1 40400 29900, Fax: +43 1 40400 29980, E-mail: bernd.jilma@meduniwien.ac.at.
Bernd
B
Jilma
D061067:Antibodies, Monoclonal, Humanized / Q000493:pharmacokinetics*; D000925:Anticoagulants / Q000493:pharmacokinetics*; D000069604:Dabigatran / Q000037:antagonists & inhibitors*; D006801:Humans; D008297:Male
D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; D000069604:Dabigatran